Galactosyltransferase II in Detection of Pancreatic Cancer

Randall D. Cebul, Richard W. Sattin, Daniel K. Podolsky, Kurt J. Isselbacher

Research output: Contribution to journalLetter

Abstract

To the Editor: Podolsky et al. (May 28 issue),1 in evaluating test batteries that include galactosyltransferase isoenzyme II (GT-II) with one of the other recommended tests, have not specifically considered previously described principles of parallel-test use. When two tests used in parallel are being considered, the criterion for a positive battery may be either that both tests' results must be abnormal or that either test's results may be abnormal. The first criterion improves the battery's aggregate specificity but sacrifices its sensitivity, whereas the more liberal second criterion enhances sensitivity at the expense of specificity.2 , 3 The authors chose the “either test.

Original languageEnglish (US)
Pages (from-to)766-767
Number of pages2
JournalNew England Journal of Medicine
Volume305
Issue number13
DOIs
StatePublished - Sep 24 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Galactosyltransferase II in Detection of Pancreatic Cancer'. Together they form a unique fingerprint.

  • Cite this